Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Sirona Biochem Corp V.SBM

Alternate Symbol(s):  SRBCF

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.


TSXV:SBM - Post by User

Post by forhandlarenon Mar 11, 2021 10:57am
251 Views
Post# 32772302

Now a profitable company!?

Now a profitable company!?Not long ago to monthly burn rate was 200.000 CAD/month, let's say 250.000 for arguments sake, which add up to 3 million CAD annually.

For each kilo TFC-1067 sold to R+F they get 8.000 USD which translates to 10.000 CAD. Let's assume that it's sold by R+F as previously communicated, representing 10.000 tubes.

Break even (not including Sirona production costs) is then 300 kg aka 3 million tubes sold annually.

Based on how the customers reacted to the launch I think it's safe to say that Sirona from now on should be proftable.

Other sources to revenue near term is payment related to SGLT2 for pets deal that should be due any day/week now as well as an deal for TFC-1067 with the stronger concentration.


<< Previous
Bullboard Posts
Next >>